Sei Investments Co. raised its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) by 136.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,840 shares of the company’s stock after buying an additional 13,164 shares during the quarter. Sei Investments Co.’s holdings in Oruka Therapeutics were worth $1,120,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in ORKA. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics during the second quarter worth about $28,000. BNP Paribas Financial Markets lifted its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. 56.44% of the stock is currently owned by institutional investors.
Oruka Therapeutics Stock Performance
NASDAQ ORKA opened at $107.40 on Thursday. The stock has a market cap of $7.11 billion, a P/E ratio of -52.91 and a beta of -0.34. Oruka Therapeutics, Inc. has a fifty-two week low of $14.03 and a fifty-two week high of $109.42. The stock has a 50 day simple moving average of $85.59 and a two-hundred day simple moving average of $61.75.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on the stock. UBS Group raised their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Barclays increased their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Wedbush reiterated an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.
View Our Latest Report on Oruka Therapeutics
Insider Activity at Oruka Therapeutics
In related news, Director Carl Dambkowski sold 105,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the transaction, the director owned 73,743 shares in the company, valued at $4,348,624.71. The trade was a 58.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the transaction, the senior vice president directly owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. The trade was a 38.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 188,406 shares of company stock valued at $12,019,683 over the last quarter. Company insiders own 23.49% of the company’s stock.
Oruka Therapeutics Profile
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
